TransCode Therapeutics appoints MicroRNA Pioneer and Dr. Frank Slack to its advisory board

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc.

BOSTON, September 08, 2022 (The Globe Newswire) – TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an RNA oncology company committed to treating cancer more effectively with RNA therapies, today announced the appointment of Frank C. Slack, Ph.D.of its advisory board.

“Dr. Slack is one of the leading scientists in the field of small non-coding RNA” Zdravka Medarova, Ph.D.Co-founder and CTO of TransCode. “Having pioneered pivotal studies demonstrating that microRNAs lead to tumorigenesis and are critical targets for cancer therapy, his guidance will prove indispensable as TransCode enters the clinical phase of development.”

Dr. Slack is Shields Warren Mallinckrodt Professor, Department of Pathology, and Director Harvard Medical School Initiative for RNA Medicine (HIRM), Beth Israel Deaconess Medical Center. Directed by Dr. Slack, the HIRM initiative harnesses the potential of RNA to revolutionize the way cancer and other diseases are treated and diagnosed. “We are excited to welcome Dr. Slack to our advisory board,” he commented. Michael Dudley, President and CEO of TransCode. “With final preparations to begin our first human studies with our lead candidate, TTX-MC138, Dr. Slack’s tremendous expertise in microRNA supports our team at an ideal time as we move into the next stage of development.”

Dr. Slack received his Bachelor’s degree from the University of Cape Town in South Africa before completing his Ph.D. in Molecular Biology at Tufts University School of Medicine. He began working on microRNAs as a postdoctoral fellow in Gary Ruvkun’s lab at Harvard Medical School, where he co-discovered the first human microRNA molecule, let-7.

Dr. Slack’s lab is at the forefront of the small RNA revolution. In addition to the joint discovery of let-7 and the demonstration that it is a tumor suppressor controlling key cancer genes such as RAS, MYC and LIN28, the Slack lab has also demonstrated that microRNAs act as key oncogenes and developed strategies to target these cancer tumors. Psychiatric treatment. Their research also extends to the discovery of extra small RNA in cancer, aging and diabetes as well as the identification of new SNPs in non-coding parts of the genome with a focus on identifying the next generation of actionable targets in cancer.

About TransCode Therapeutics

TransCode is an RNA oncology company built on the belief that cancer can be effectively treated with RNA therapies. The company has created a platform of drug candidates designed to target a variety of tumor types with the goal of dramatically improving patient outcomes. The company’s lead therapeutic candidate, TTX-MC138, focuses on treating metastatic cancer, which is believed to cause nearly 90% of all cancer deaths totaling more than nine million annually worldwide. The company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian, colon, glioblastoma and others. Two of the company’s other candidate drugs, TTX-siPDL1 and TTX-siLIN28B, focus on treating tumors by targeting PD-L1 and LIN28B, respectively. TransCode also has three cancer-neutralizing programs – TTX-RIGA, a retinoic acid-stimulated gene 1 RNA agonist, or the RIG-I approach, designed to drive an immune response in the tumor microenvironment. TTX-CRISPR, a CRISPR/Cas9-based therapy platform to repair or eliminate cancer-causing genes within cancer cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses against cancer cells.

forward-looking statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding TransCode management and the advisory board, statements regarding the results of RNA research, and statements regarding the possibility of cancer treatment. With RNA therapies, data regarding timing and outcome of expected regulatory filings and clinical trials, including eIND’s submission of the planned first in-human study of TTX-MC138, and data regarding timing and outcome of this study, including whether this study will demonstrate proof of the mechanism , data on patent applications, data on TransCode development software and the TTX technology platform in general. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and negatively from those set forth in or implied by such future expectations. formulations. These risks and uncertainties include, but are not limited to: risks associated with drug discovery and development; risk of inconsistent results of planned clinical trials with our preclinical studies or expectations; Risks associated with the timing and outcome of TransCode’s planned regulatory filings; risks associated with TransCode’s planned clinical trials of its product candidates; risks associated with acquiring, maintaining and protecting intellectual property; Risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; competition risks from other companies that develop products for similar uses; Risks related to TransCode’s financial condition and its need to obtain additional financing to support its business activities, including TransCode’s ability to continue as a going concern; Risks associated with TransCode’s reliance on third parties; and risks associated with COVID-19. For a discussion of these risks and other uncertainties and other important factors, any of which could cause TransCode’s actual results to differ from those contained or implied by forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Annual Report on Form 10-K for the year ended December 31, 2021, as well as discussions of potential risks, uncertainties and other significant factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release; TransCode has no duty to update this information unless required by law.

For more information please contact:

TransCode Therapeutics, Inc.
Alan Friedman, Vice President of Investor Relations

Dave Gentry, CEO
RedChip Companies
Office: 1.800.RED.CHIP (733.2447)
Cell: 407.491.4498

Leave a Comment